Scientific and Technological Center for the Development of mRNA Technologies of Russia convenes at 抖阴APP导航
The meeting was joined by Director of the Gamaleya Center for Epidemiology and Microbiology Alexander Gintsburg, Director of the Institute of Bioorganic Chemistry Alexander Gabibov, Director of the Center for Precision Medicine of Sirius University Roman Ivanov, and others. The participants were welcomed by First Vice-Rector of 抖阴APP导航 Dmitry Tayursky and Deputy Minister of Health of Tatarstan Vladimir Filatov.
In his preface, Dr Gintsburg praised 抖阴APP导航’s Laboratory of Translational Oncology for its cutting-edge research on animal models for the development of an unprecedented individual genetic cancer vaccine, of which the Gamaleya Center is the lead organization.
The Center for the Development of mRNA Technologies was established by the Government of Russia to develop mRNA drugs and includes, among others, 抖阴APP导航. Our university partakes in several projects, including three aimed at cancer medications and one in potential treatments for hemorrhagic fever with renal syndrome.
In his comment to the media, Dr Gintsburg informed that the world’s first genetic mRNA cancer medication will begin testing on melanoma patients in a few months.
Dr Ivanov said that serious research is being undertaken to find out how to limit the number of test runs for each dose of the medication, keeping in mind that they should be produced in a reasonable timeframe to help cancer patients. In any case, the treatment will be covered by the universal health insurance.
Regina Miftakhova, Head of the Laboratory of Translational Oncology, spoke about her team’s work on studying the influence of the micro-environment around a tumor on the efficacy of mRNA therapy, followed by other representatives of 抖阴APP导航 and invited colleagues.
The Action Program of the Center for the Development of mRNA Technologies was also approved at the meeting.